CurrentColorado Rocky Mountain Health PlansPolicy 2026D0063K

Trogarzo (ibalizumab-uiyk) coverage for multidrug-resistant HIV-1

Defines UnitedHealthcare coverage criteria for Trogarzo (ibalizumab-uiyk) for adults with multidrug-resistant HIV-1 for commercial and individual exchange plans; describes initial and continuation authorization requirements and applicable coding. Affects providers seeking prior authorization for this drug.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyTrogarzo (ibalizumab-uiyk) coverage for multidrug-resistant HIV-1

Policy CodePolicy 2026D0063K

Change TypeNo material change

Effective DateJun 1, 2026

Next Review Date

Key ActionObtain prior authorization with provider attestation of multidrug-resistant HIV-1, confirmation of an optimized background antiretroviral regimen, and ensure dosing follows FDA prescribing information.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≤12 moauthorization length

J1746HCPCS

Heavily treatedFDA indication

24-wk trialKey evidence

Coverage Criteria for Trogarzo (ibalizumab-uiyk)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

inv-01: Initial Therapy

Covered when ALL of the following are met for initial therapy:

Initial Therapy

Diagnosis and attestation: Diagnosis of HIV-1 infection AND provider attestation that the patient has multi-drug resistant HIV-1 infection
Provider attestation required
Optimized background regimen: Provider confirms the patient has been prescribed an optimized background antiretroviral regimen containing at least one antiretroviral agent that demonstrates full viral sensitivity/susceptibility
Dosing: Trogarzo (ibalizumab-uiyk) initial and maintenance dosing is in accordance with the U.S. FDA prescribing information
Authorization length: Initial authorization is for no more than 12 months<= 12 months

Provider attestation note: Provider attestation that the patient has multi-drug resistant HIV-1 infection is required to support medical necessity

Per DHHS guidance, ibalizumab is not recommended as initial therapy for routine first-line management of HIV‑1; it is reserved for patients who lack sufficient treatment options to construct a fully suppressive regimen. Providers should position ibalizumab accordingly when considering therapy sequencing and discuss why standard first‑line antiretroviral regimens are not appropriate for the patient. Use of ibalizumab is generally limited to cases where alternative, guideline‑recommended regimens are ineffective or unavailable, and clinical justification and documentation of multidrug resistance are required.

Provider Actions and Authorization Requirements

Prior Authorization

Prior Authorization Required

Prior Authorization Required. Initial and continuation therapy require prior authorization. Initial authorizations are limited to a maximum of 12 months; continuation authorizations are also limited to no more than 12 months per approval.

A prior authorization attestation from the provider that the patient has multi-drug resistant HIV-1 is required.
Provider must confirm an optimized background antiretroviral regimen is being prescribed (contains ≥1 agent with documented full viral sensitivity).
Dosing must follow FDA prescribing information; initial and maintenance dosing must be documented.
Applicable codes: J1746 (injection, ibalizumab-uiyk, 10 mg); diagnosis codes commonly used: B20, Z16.33, Z21.

Step Therapy

Step Therapy / Positioning

Step therapy / positioning. Per DHHS guidance, ibalizumab is not recommended as initial antiretroviral therapy and is reserved for patients with limited treatment options (e.g., ongoing detectable viremia and insufficient options for a fully suppressive regimen). Document prior use and failure or resistance to other agents as applicable.

Provider attestation that patient has multi-drug resistant HIV-1 is required before approval.
Evidence that other regimen options have been considered or exhausted should be included in the medical record to support use.

Documentation Required

Required Documentation

Required documentation. Include provider attestation of multi-drug resistant HIV-1, documentation of the optimized background antiretroviral regimen (agents and susceptibility results), prior treatment history, and dosing plan consistent with FDA labeling.

Documented diagnosis of HIV-1 (e.g., B20) and drug resistance where applicable (e.g., Z16.33).
Laboratory or resistance testing supporting choice of background regimen and at least one fully susceptible agent.
Records showing prior receipt of Trogarzo for continuation requests and demonstration of clinically significant viral response for renewal.
Requested authorization duration (initial or continuation) and planned dosing schedule per FDA labeling.

Denial Risk

Conditions That May Lead to Denial

Denial-risk conditions. Claims or authorizations may be denied if required attestations or documentation are missing, if optimized background regimen is not confirmed, or if dosing is inconsistent with FDA labeling.

Missing provider attestation of multi-drug resistant HIV-1.
No documentation that an optimized background antiretroviral regimen (with ≥1 fully susceptible agent) is being used.
Dosing that does not follow FDA-approved initial or maintenance schedules.
Lack of prior-treatment history or absence of evidence of clinically significant viral response for continuation requests.

Key Definitions

Multidrug-resistant (MDR) HIV-1 — definition and supporting detail

DefinitionHIV-1 infection demonstrating resistance to multiple approved antiretroviral agents such that standard regimens are insufficient; provider attestation of multidrug-resistant (MDR) HIV-1 is required.

Clinical significanceTrogarzo (ibalizumab-uiyk) is active against HIV-1 resistant to approved antiretroviral agents and is intended for heavily treatment‑experienced patients failing their current regimen.

Mechanism relevant to MDRIbalizumab binds the second extracellular domain of the CD4 receptor, blocking HIV entry into CD4+ cells while preserving normal immune function—effective against viruses resistant to other classes.

Regulatory contextFDA indicates ibalizumab for heavily treatment‑experienced adults with multi‑drug resistant HIV‑1 in combination with other antiretrovirals.

Documentation noteProvider attestation of MDR status is required to support use of ibalizumab for multidrug‑resistant HIV‑1.

Background — Drug and Indication

Trogarzo (ibalizumab‑uiyk) is a humanized monoclonal antibody that binds the second extracellular domain of CD4, blocking HIV‑1 entry into CD4+ cells and retaining activity against viruses resistant to other antiretroviral classes. The agent is indicated for heavily treatment‑experienced adults with multidrug‑resistant (MDR) HIV‑1 who are failing their current antiretroviral regimen. Administration is intravenous per the U.S. FDA prescribing information; initial dosing includes an IV loading dose followed by maintenance infusions, and treatment should follow labeled dosing schedules.

OpenPayer

Trogarzo (ibalizumab-uiyk) coverage for multidrug-resistant HIV-1

Coverage Criteria for Trogarzo (ibalizumab-uiyk)

Applicable Coding

Provider Actions and Authorization Requirements

Key Definitions

Background — Drug and Indication

B20	Human immunodeficiency virus [HIV] disease.
Z16.33	Resistance to antiviral drug(s).
Z21	Asymptomatic human immunodeficiency virus [HIV] infection status